---
title: Hyperkalemia
author: J. Austin Straley, DO
layout: post
chapter: 05
section: 02
lesson: '03'
date: 2022-11-26
---

<html>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <link href="{{site.baseurl}}/assets/grid/bootstrap-grid.min.css" rel="stylesheet">
    <link href="{{site.baseurl}}/assets/grid/grid.css" rel="stylesheet">
    <link rel="stylesheet" href="{{site.baseurl}}/assets/gitbook/gitbook-plugin-fontsettings/website.css">
    <link rel="stylesheet" href="{{site.baseurl}}/assets/gitbook/gitbook-plugin-search-pro/search.css">
    <link rel="stylesheet" href="{{site.baseurl}}/assets/gitbook/gitbook-plugin-back-to-top-button/plugin.css">
    <link rel="stylesheet" href="{{site.baseurl}}/assets/gitbook/style.css">
    <link rel="stylesheet" href="{{site.baseurl}}/assets/gitbook/rouge/{{ site.syntax_highlighter_style | default: 'colorful' }}.css">
    <meta name="HandheldFriendly" content="true"/>
    <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no">
    <meta name="apple-mobile-web-app-capable" content="yes">
    <meta name="apple-mobile-web-app-status-bar-style" content="black">
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="{{site.baseurl}}/assets/gitbook/images/apple-touch-icon-precomposed-152.png">
    <link rel="shortcut icon" href="{{site.baseurl}}/{{site.favicon_path}}" type="image/x-icon">
    <style>
        .p {
            color: #B8B8B8;
        }
        .p1 {
            color
        }
    </style>
</html>

-   Definition: Serum Potassium >5.0 mEq/L
-	[General][3]
    -	Renal impairment (decreased renal excretion)
        -	Type IV RTA
        -	Hypoaldosteronism, AKD, CKD (Renal failure w/oliguria or GFR <15)
    -   Intracellular space circulation impairment (Acid-base, illness, medication)
        -	Uncontrolled hyperglycemia
            -	Insulin Deficiency, Hyperosmolar State, DKA
        -	Acidosis
        -	Rhabdomyolysis, Hematoma, Trauma
        -	Tumor lysis syndrome if cancer patient
        -	Drugs causing Hyperkalemia: 
            -	Non-selective BB – inhibits beta-2-mediated intracellular potassium uptake
                -	Labetalol
            -	ACEI, ARBs – inhibit ATII and AT1 receptor, decreased aldosterone secretion
            -	K+ sparing diuretics – inhibits aldosterone or the ENaC channel
                -	Amiloride, triamterene switch to amlodipine (f/u in 1 week)
                -	Spironolactone, eplerenone
            -	Digitalis/Digoxin – inhibition of the Na-K-ATPase pump
            -	Cyclosporine/Tacrolimus – blocks aldosterone activity
            -	Heparin – blocks aldosterone production
            -	NSAIDs – decreases renal perfusion resulting in decreased K+ delivery to CD
            -	Trimethoprim (increased Creatine, inhibits secretion), TMP/SMX
                -	Pentamidine, Ketoconazole, IV Penicillin G
            -	Succinylcholine – causes extracellular leakage of potassium through AchR
            -	pRBC transfusions
            -	Normal Saline (Hyperchloremic Metabolic Acidosis)
    -   Increased Intake
        -   Bananas, melons, citrus juice, potatoes
        -	Salt substitutes
    -	Pseudohyperkalemia (hemolyzed blood sample)
        -	Transient, insignificant elevation in K+ levels prior to sampling
        -	Hemolysis, Repeated fist clenching, Severe leukocytosis or thrombocytosis, Delayed sample processing
-	Symptoms:
    -	Palpitations, syncope, SCD
        -	Cardiac Arrythmias, bradycardia
    -	No AMS or seizures
    -	Severe, ascending muscle weakness
        -	+/- flaccid paralysis, hypoventilation
    -	EKG
        -	First: Increased T-wave amplitude, “peaked” T-waves
            -	Prolonged PR, loss of P waves
        -	Late: Widening QRS, sine wave pattern
            -	Conduction block ectopy
            -	Can progress to sinus bradycardia, sinus arrest, Vfib
-	W/U (if unknown cuase): 
    -   Urine K+ Excretion, Plasma renin, serum aldosterone, serum cortisol, EKG
    -	Trans-tubular K+ gradient [(TTKG)][1]
        -   Not commonly utilized anymore
        -	TTKG = (Urine K/Serum K) / (urine osmol/serum osmol)
            -	>10: appropriate increase in renal excretion
            -	<7: Aldosterone deficiency or resistance
    -	Measure CK and LDH for lysis
    -	+/- Random cortisol/ACTH stim tests
-	Management
    -	1) Get EKG
        -	Mild: 5.0-5.9 w/o EKG changes
            -	Loop or Thiazide diuretics + LR
            -	Discontinue ACEIs/Spironolactone (treat reversible causes)
        -	Moderate: 5.0-5.9 w/EKG changes or 6.0-6.4 w/o EKG changes
            -	IV Lasix (60-160mg) followed by LR
        -	Severe: K ≥6.5-7.0, EKG changes, or Cardiac Toxicity
            -	1) Evaluate Volume Status
                -	Low: A
                -	Otherwise: C
            -	A) If hypovolemic and needing volume resuscitation
                -	Target euvolemia with a bicarb of 24-28mM
                -	Low Bicarb (metabolic acidosis): Isotonic Bicarb (D5W with 150 mEq/L sodium bicarb aka 3 amps of bicarb)
                    -	Will likely need 1-2L (dose by dividing bicarb deficit by 150 to estimate number of needed liters)
                    -	Rate of 500-1000ml/hr
                    -	Decreases K by: dilution, shifting, and excretion
                -	Normal/High bicarb (No acidosis): LR or plasmalyte/Normosol
                -	NO Normal Saline
            -	B) Temporizing measures
                -	Cardiac Membrane Stabilization (prevents arrhythmias)
                    -	Always given if K >6.5 or EKG changes
                    -	Only lasts 30-60 minutes, may need to be re-dosed
                        -	HyperK is more dangerous than hypercalcemia
                    -	1) IV Calcium Gluconate (3g) peripherally over 10 minutes or Calcium Chloride (1g) over 10minutes/slow push
                -	Rapidly acting treatment options
                    -	1) 5U IV Insulin bolus followed by Glucose 
                        -	If glucose <250 give 2 amps D50W < D10W 500mL infusion over 2 hours
                        -	>250 may hold dextrose
                        -	Finger stick glucose for 4-6 hours
                        -	Lasts a few hours
                -	+/- Beta 2 agonists (Albuterol) 10-20mg nebulized, likely continuous neb
                -	+/- Sodium Bicarbonate (if metabolic acidosis too)
                -	+/- IV Epinephrine
                    -	Great for hyperkalemia induced bradycardia
            -	C) Elimination
                -	Removal of potassium from the body slowly
                -	Diuretics (furosemide or thiazides)
                    -	If near normal renal function: 60-120mg IV lasix
                    -	Near Dialysis: 80-160mg IV Lasix + (500-1000 IV chlorothiazide or PO 5-10mg metolazone) + 250-1000 acetazolamide PO/IV
                        -	Nephron bomb if all at max doses
                    -	+/- 0.2mg fludrocortisone
                        -	Works for all except obstructive uropathy, transplants, most drugs, SLE, sickle cell
                        -	Best for ACEI/ARBs/NSAIDs
                    -	Give balanced crystalloid to prevent hypovolemia
                        -	LR or isotonic bicarb
                -	Dialysis if failure
            -	D) Elimination
                -	Cation exchange resins 
                    -	Sodium polystyrene sulfonate (Kayexalate)
                        -	Promotes Na+/K+ exchange in intestine, increased in stool
                        -	SE: Intestinal necrosis
                        -	CI: Post-op patients
                    -	Sodium Zirconium cyclosilicate (Lokalema)
                        -	0.2mM reduction within 4 hours, 0.4mM reduction in 24 hours
                -	Doesn’t work for anuric patients
                        -	Mildly effective, may prevent or delay dialysis
                        -	10mg PO q8hrs

- References
    - 2007091017: Choi M, Ziyadeh F. The utility of the transtubular potassium gradient in the evaluation of hyperkalemia. J Am Soc Nephrol 2008; 19:424–426.

[1]: https://www.mdcalc.com/calc/3944/transtubular-potassium-gradient-ttkg
[2]: https://doi.org/10.1681/ASN.2007091017
[3]: https://doi.org/10.3949/ccjm.84a.17056